Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Conditions
Interventions
Intismeran autogene
Pembrolizumab
+1 more
Locations
165
United States
Highlands Oncology Group ( Site 1943)
Springdale, Arkansas, United States
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)
Los Angeles, California, United States
UCSF Medical Center at Mission Bay ( Site 1929)
San Francisco, California, United States
Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)
New Haven, Connecticut, United States
Orlando Health Cancer Institute ( Site 1937)
Orlando, Florida, United States
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)
Tampa, Florida, United States
Start Date
July 19, 2023
Primary Completion Date
October 26, 2029
Completion Date
September 26, 2030
Last Updated
September 24, 2025
NCT07177937
NCT02621021
NCT03050268
NCT03340506
NCT05969860
NCT04693377
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions